bioAffinity Technologies Raises $3.2M in Public Offering
Event summary
- bioAffinity Technologies raised $3.2M through a public offering of 4M shares at $0.80 per share.
- The offering includes pre-funded warrants exercisable for common stock.
- WallachBeth Capital acted as sole placement agent for the deal.
- Closing is expected on June 18, 2026, subject to customary conditions.
The big picture
This $3.2M offering reflects bioAffinity's push to scale its noninvasive lung cancer detection technology, a critical area in early-stage diagnostics. The deal underscores WallachBeth Capital's role in connecting biotech firms with institutional investors, particularly in niche healthcare segments. The success of this offering could signal broader market appetite for innovative diagnostic tools amid rising demand for early disease detection.
What we're watching
- Execution Risk
- Whether bioAffinity can deploy the $3.2M effectively to advance its noninvasive lung cancer detection technology.
- Market Dynamics
- How this funding round positions bioAffinity against competitors in the early-stage lung cancer diagnostics space.
- Regulatory Compliance
- The pace at which bioAffinity can navigate SEC filings and other regulatory requirements post-offering.